Successful treatment of pure red cell aplasia in systemic lupus erythematosus with erythropoietin

H. Orbach, A. Ben-Yehuda, D. Ben-Yehuda, D. Manor, A. Rubinow, Y. Naparstek*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

We describe a 32-year-old woman who developed severe anemia due to pure red cell aplasia in the course of systemic lupus erythematosus (SLE). After failure of therapy with high doses of glucocorticoids and immunoglobulins, and despite high levels of endogenous erythropoietin, she was treated with human recombinant erythropoietin with dramatic and sustained improvement. Based on this case and on the literature review of erythropoietin therapy in pure red cell aplasia, we suggest that erythropoietin should be used in SLE associated pure red cell aplasia before cytotoxic therapy.

Original languageAmerican English
Pages (from-to)2166-2169
Number of pages4
JournalJournal of Rheumatology
Volume22
Issue number11
StatePublished - 1995
Externally publishedYes

Keywords

  • Erythropoietin
  • Red cell aplasia
  • Systemic lupus erythematosus

Fingerprint

Dive into the research topics of 'Successful treatment of pure red cell aplasia in systemic lupus erythematosus with erythropoietin'. Together they form a unique fingerprint.

Cite this